BCM
ANIP icon

Bayesian Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Bayesian Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,500
Closed -$1.05M – 134
2025
Q3 		$1.05M Buy
+11,500
New +$938K 0.22% 152
2025
Q2 		– Sell
-5,447
Closed -$365K – 534
2025
Q1 		$365K Buy
+5,447
New +$325K 0.06% 350
2024
Q4 		– Sell
-6,239
Closed -$372K – 674
2024
Q3 		$372K Buy
+6,239
New +$381K 0.04% 431

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayesian Capital Management's ANIP Position: Q4 2025 in Review

Bayesian Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 11,500 shares — an estimated $1.05M sold.

Bayesian Capital Management first reported a position in ANIP in Q3 2024 and held it in 3 quarters. The position peaked at $1.05M in Q3 2025. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • Bayesian Capital Management reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 11,500 ANI Pharmaceuticals shares in Q4 2025, an estimated $1.05M.
  • Bayesian Capital Management first reported a position in ANI Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Bayesian Capital Management's ANI Pharmaceuticals position peaked at $1.05M in Q3 2025.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.